From the Grateful Dead’s tour bus to the FDA’s approval queue, from “turn on, tune in, drop out” to potentially “take two doses and see me in a year,” this is the improbable journey of psychedelics in 2025. We now live in a world where a ketamine analog marketed by Johnson & Johnson could provide… The post Why Cybin’s CEO sees RFK Jr. and J&J’s ketamine clinics as keys to clinical psilocybin’s mainstream moment appeared first on Drug Discovery and Development.
